Taro Pharmaceutical Industries (FRA:TAL) 3-Year EPS without NRI Growth Rate : -50.50% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Taro Pharmaceutical Industries 3-Year EPS without NRI Growth Rate?

Taro Pharmaceutical Industries's EPS without NRI for the three months ended in Dec. 2023 was €0.49.

During the past 12 months, Taro Pharmaceutical Industries's average EPS without NRI Growth Rate was 0.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was -50.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was -35.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was -21.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Taro Pharmaceutical Industries was 155.90% per year. The lowest was -54.20% per year. And the median was 27.60% per year.

Competitive Comparison of Taro Pharmaceutical Industries's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taro Pharmaceutical Industries's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's 3-Year EPS without NRI Growth Rate falls into.

Taro Pharmaceutical Industries 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Taro Pharmaceutical Industries (FRA:TAL) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Taro Pharmaceutical Industries 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Taro Pharmaceutical Industries (FRA:TAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (FRA:TAL) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

TARO:USA

Address

14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761

Website

https://www.taro.com

Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.